Amgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics.
FILE - This photo shows signage outside the Amgen headquarters in Thousand Oaks, Calif on Nov. 9, 2014. Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion.
The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye disease that generated more than $1 billion in its first full year on the market.U.S.-traded shares of the Irish company had already soared about 30% since it confirmed late last month that it had begun “highly preliminary discussions” about an acquisition with Amgen, the French drugmaker Sanofi, and Johnson & Johnson’s Janssen division.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.
Weiterlesen »
Amgen reportedly in talks to buy Horizon TherapeuticsThe U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
Weiterlesen »
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen Inc. undefined said Monday it has agreed to acquire Horizon Therapeutics Plc undefined in an all-cash deal valued at $27.8 billion, confirming earlier...
Weiterlesen »
Amgen Agrees to Deal to Buy Horizon TherapeuticsThe U.S. biotech company agreed to buy drugmaker Horizon Therapeutics in a deal valued at $27.8 billion, marking the largest healthcare merger of the year.
Weiterlesen »
WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
Weiterlesen »
Amgen emerges frontrunner in Horizon deal as Sanofi drops bidAmgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc , the Wall Street Journal reported on Sunday, while rival bidder French health group Sanofi announced it had dropped its bid.
Weiterlesen »